[go: up one dir, main page]

WO2003040371A1 - Nouvelle proteine du recepteur couple a la proteine g et adn associe - Google Patents

Nouvelle proteine du recepteur couple a la proteine g et adn associe Download PDF

Info

Publication number
WO2003040371A1
WO2003040371A1 PCT/JP2002/011485 JP0211485W WO03040371A1 WO 2003040371 A1 WO2003040371 A1 WO 2003040371A1 JP 0211485 W JP0211485 W JP 0211485W WO 03040371 A1 WO03040371 A1 WO 03040371A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
dna
novel
coupled receptor
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/011485
Other languages
English (en)
Japanese (ja)
Inventor
Natsuki Ikeda
Masanori Miwa
Takashi Ito
Tetsuya Ohtaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of WO2003040371A1 publication Critical patent/WO2003040371A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)

Abstract

L'invention concerne une protéine d'origine humaine et un ADN codant cette protéine, qui peuvent être utilisés: 1) pour déterminer un ligand de ladite protéine; 2) dans des substances préventives ou thérapeutiques contre des maladies associées à l'hypofonction de la protéine; 3) pour cribler un composé, etc., pouvant modifier les propriétés de liaison de la protéine au ligand, etc.
PCT/JP2002/011485 2001-11-06 2002-11-05 Nouvelle proteine du recepteur couple a la proteine g et adn associe Ceased WO2003040371A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001-340189 2001-11-06
JP2001340189 2001-11-06
JP2002159448 2002-05-31
JP2002-159448 2002-05-31

Publications (1)

Publication Number Publication Date
WO2003040371A1 true WO2003040371A1 (fr) 2003-05-15

Family

ID=26624364

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/011485 Ceased WO2003040371A1 (fr) 2001-11-06 2002-11-05 Nouvelle proteine du recepteur couple a la proteine g et adn associe

Country Status (1)

Country Link
WO (1) WO2003040371A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999015660A1 (fr) * 1997-09-24 1999-04-01 Merck & Co., Inc. Recepteur hormonal hg38 de glycoproteine couple a la proteine g
EP0950711A2 (fr) * 1998-02-06 1999-10-20 Akzo Nobel N.V. Récepteurs de Gonadotropine
WO2001085768A2 (fr) * 2000-05-08 2001-11-15 Millennium Pharmaceuticals, Inc. Nouveaux recepteurs couples a la proteine g et utilisations de ceux-ci
WO2002026825A2 (fr) * 2000-09-29 2002-04-04 Incyte Genomics, Inc. Récepteurs couplés à la protéine g

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999015660A1 (fr) * 1997-09-24 1999-04-01 Merck & Co., Inc. Recepteur hormonal hg38 de glycoproteine couple a la proteine g
EP0950711A2 (fr) * 1998-02-06 1999-10-20 Akzo Nobel N.V. Récepteurs de Gonadotropine
WO2001085768A2 (fr) * 2000-05-08 2001-11-15 Millennium Pharmaceuticals, Inc. Nouveaux recepteurs couples a la proteine g et utilisations de ceux-ci
WO2002026825A2 (fr) * 2000-09-29 2002-04-04 Incyte Genomics, Inc. Récepteurs couplés à la protéine g

Similar Documents

Publication Publication Date Title
IL200404A0 (en) 191P4D12(b) PROTEINS, POLYNUCLEOTIDES ENCODING THE SAME; ANTIBODIES BINDING THERETO AND USES THEREOF
WO2002002636A3 (fr) Proteine zupar i associee a une membrane
WO2006060513A3 (fr) Antagonistes du recepteur toll-3, methodes et applications
AU2002314181A1 (en) Novel endothelially expressed dnas and proteins, and their use
WO2005087793A3 (fr) Compositions immunostimulatrices et leurs utilisations
MXPA03007635A (es) P-tienilbencilamidas que sirven como agonistas de receptores para angiotensina-(1-7), metodo para su produccion, su uso y preparaciones farmaceuticas que las contienen.
WO2001085792A3 (fr) Mu-1, membre de la famille des recepteurs de la cytokine
AU2002365269A1 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
WO2003020759A3 (fr) Proteine de liaison de caspase 8, ses procedes de preparation et son utilisation
WO2003040371A1 (fr) Nouvelle proteine du recepteur couple a la proteine g et adn associe
WO2006063028A3 (fr) Compositions immunostimulantes et utilisations de celles-ci
WO2003008445A1 (fr) Nouvelle proteine receptrice couplee a la proteine g, et adn codant pour elle
EP1501870A4 (fr) Proteines du vrs, anticorps, compositions, procedes et utilisations
WO2002061083A1 (fr) Nouvelle proteine de recepteur couple aux proteines g et son adn
WO2002061075A1 (fr) Proteine de recepteur couple aux proteines g et adn correspondant
WO2005026207A3 (fr) Proteine zacrp12 provenant des adipocytes et en relation avec le complement
AU2002325299A1 (en) Novel t-cell proteins, peptides and antibodies derived therefrom and uses thereof
WO2001090183A3 (fr) Proteine humaine secretee zsig47
WO2002050274A3 (fr) Proteine zsel1 contenant de la selenocysteine
WO2002062996A1 (fr) Nouveau peptide physiologiquement actif et utilisation de ce peptide
WO2003090514A3 (fr) Proteine zacrp14 associee a un complement d'adipocyte
WO2003091414A3 (fr) Proteine zacrp8 parente du complement de l'adipocyte
AU2002368307A1 (en) Soluble truncated polypeptides of the nogo-a protein
WO2001021794A3 (fr) Polypeptides associant smad
AU2002253614A1 (en) Nove g protein-coupled receptor protein and dna thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP